News – Page 1078 – Endpoints News

Cynthia Collins exits Human Longevity; Section 32 welcomes Michael Pellini; Silverback beefs up its C-suite

8 years ago

In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib

8 years ago

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

8 years ago

Sexual harassment in biotech hits home as OrbiMed’s Sam Isaly steps down in wake of STAT report

8 years ago

Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs

8 years ago

Daniel Swisher leaves an ailing Sunesis and swoops in to lead Jazz Pharmaceuticals

8 years ago

Canada's AmorChem launches $44.2M life science fund; Neon adds $36M, Merck partnership in neoantigen drive; CRISPR ...

8 years ago

Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform

8 years ago

Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris

8 years ago

Sage triggers another burst of investor enthusiasm as oral depression drug scores in PhII

8 years ago

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

8 years ago

There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?

8 years ago

Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug

8 years ago

Looking for a come-from-behind win, Roche touts its pivotal success for Tecentriq combo in front-line lung cancer

8 years ago

More efficient rare pediatric drug development: FDA drafts guidance

8 years ago

Athyrium raises $2B for debt/equity fund; Amgen teams with Carmot on Parkinson's; Neuralstem soars on failed study(?)

8 years ago

Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA

8 years ago

Madrigal's stock soars on promising PhII data in NASH, but questions linger

8 years ago

Cancer R&D tips the scales at the FDA as active INDs climb to record high

8 years ago

After building expectations, the UK’s life sciences plan falls short of the hype

8 years ago

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round

8 years ago

Clinical trial transparency improves at (some) biopharmas as J&J, Sanofi lead a pack trailed by Valeant and Allergan

8 years ago

Merck and PhRMA to FDA: Wait for ICH before finalizing guidance on toxicity testing for cancer drugs

8 years ago

In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic

8 years ago

First page Previous page 1075 1076 107710781079 1080 1081 Next page Last page